Ervebo is a recombinant, replication-competent Ebola vaccine, originally developed by NewLink Genetics and licensed to Merck in 2014, that has been given to hundreds of thousands of people in the ...

View Full Profile. Learn about our Editorial Policies. Ervebo, an Ebola vaccine from Merck, received marketing approval from the European Commission today (November 11), marking the first such vaccine ...

As Ebola swept through Sierra Leone in 2014, there were no approved vaccines against the disease. In 2019, the WHO prequalified the Ervebo vaccine and Gavi formally approved the establishment of a ...

This is the second Ebola vaccine approved by the European Commission: in November it granted a marketing authorisation to MSD’s vaccine known as Ervebo. This vaccine has been shown to produce ...

It is also necessary for people visiting regions affected by Ebola to get vaccinated before they travel. Ervebo is a live-attenuated vaccine. That means it contains a weakened protein from EVD ...

Vaccines have been increasingly important in curbing recent Ebola outbreaks. Health authorities vaccinated more than 1,800 people using Merck's (MRK.N) ERVEBO vaccine amid the last flare-up.